Most Read Articles
Yesterday
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Tristan Manalac, 5 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
3 days ago
Resistance training appears to confer significant benefits for inflammation and insulin pathway profiles in postmenopausal breast cancer survivors, according to a study. However, the magnitude and degree of benefit from exercise may be influenced by whether or not women gained strength and/or lost weight during exercise.
Pearl Toh, 2 days ago
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.

Liquid biopsy a promising tool for monitoring patients with bladder cancer

Dr. Joseph Delano Fule Robles
17 Aug 2017

Detection of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and microRNA (miRNA) using blood samples (liquid biopsy) instead of cancer tissue proved useful in detecting progression and predicting prognosis of patients with bladder cancer, according to data presented at the recent 15th Urological Association of Asia Congress (UAA 2017) held in Hong Kong.

“Tumour heterogeneity is a problem in profiling bladder cancer. This may be resolved by doing biopsies of multiple foci, but this is invasive for the patients. Liquid biopsy can provide a temporal, genetic landscape of the cancer in a less invasive manner,” said Dr Masayoshi Nagata of the Department of Urology, Juntendo University, Tokyo, Japan.

In a pilot study of 12 patients with bladder cancer, CTCs were detected by CytoQuest in 92 percent of the patients. There was no significant difference in the number of median CTCs before (median, 7; range 1–16) and after transurethral resection of bladder tumour (TUR-Bt) (median, 7; range 2–26). [Nagata M, et al, UAA 2017; http://www.abnova.com/products/CytoQuest-CR-M0014.html]

“These results demonstrated that performance of TUR-Bt did not cause dissemination of the tumour,” Nagata said.

In a study of 188 patients who underwent radical cystectomy (RC) without neoadjuvant chemotherapy, CTCs were noted to be present in 21 percent of patients. The detection of CTCs correlated with reduced recurrence-free survival (RFS) and cancer-specific survival (p≤0.016). [BJU Int 2017;119:854-861]

In another study, 11 percent of 403 bladder cancer patients who underwent RC were found to have FGFR3 and P1K3CA high mutated DNA in ctDNA analysis, which showed significant correlation with poor RFS (p=0.031). [Eur Urol 2017;71:961-969]

“The results of this study showed that ctDNA from patients with bladder cancer can be monitored for disease progression and detection of metastasis,” commented Nagata.

A retrospective pilot study of 377 samples from 12 patients with recurrent or progressive/metastatic bladder cancer showed significantly higher levels of ctDNA in plasma and urine before disease progression (p=0.032) vs patients with recurrent disease (p=1.3×10-6). [Eur Urol 2016;70:75-82]

In genome-wide analyses of serum miRNA in 207 patients with muscle-invasive bladder cancer (MIBC), low expression of the miRNAs miR-486-3p (p=0.002) and miR-103a-3p (p=0.034) was noted to be correlated to worse overall survival. [Oncotarget 2016;7:36733-36742]

“Serum miRNA signatures might have considerable clinical values in predicting and providing prognostic information in MIBC,” Nagata said.

“Detection and quantification of CTCs, ctDNA and miRNA by liquid biopsy can temporally provide the genetic landscape of bladder cancer in a less invasive manner, although circulating biomarkers are not yet established in clinical practice… In the future, liquid biopsy will serve as a tool for the selection of effective precision medicine for bladder cancer patients,” he concluded. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Yesterday
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Tristan Manalac, 5 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
3 days ago
Resistance training appears to confer significant benefits for inflammation and insulin pathway profiles in postmenopausal breast cancer survivors, according to a study. However, the magnitude and degree of benefit from exercise may be influenced by whether or not women gained strength and/or lost weight during exercise.
Pearl Toh, 2 days ago
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.